Recent Finacing
Recent Raise
Rain Therapeutics develops biomarker-driven small‑molecule oncology drugs, advancing MDM2 inhibitor RAIN‑32 for WD/DD liposarcoma and tarloxotinib, a hypoxia‑activated pan‑ErbB prodrug, for NSCLC with EGFR/HER2/NRG1 alterations.
